Abstract:This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have focal epilepsy. Vigabatrin is an antiepileptic drug licensed for use in drug‐resistant epilepsy. To assess the efficacy and tolerability of vigabatrin as an add‐on therapy for people with drug‐resistant focal epilepsy. For the latest update of this review, we searched the following databases on 1 November 2018: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid 1946 to 31 October 2018), ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. The Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL) are both included in the Cochrane Register of Studies (CRS Web). We checked reference lists of retrieved studies for additional reports of relevant studies and contacted Hoechst Marion Roussel (manufacturers of vigabatrin) in 2000. We included randomised, double‐blind, placebo‐controlled, fully published trials of vigabatrin in people of any age with drug‐resistant focal epilepsy. Two review authors assessed trials for inclusion and extracted data using the standard methodological procedures expected by Cochrane. Primary analysis was by intention‐to‐treat (ITT). We evaluated: 50% or greater reduction in seizure frequency, treatment withdrawal, adverse effects, dose‐response analysis, cognitive outcomes and quality of life. We presented results as risk ratios (RR) with 95% or 99% confidence intervals (CI). We identified 11 trials that included 756 participants (age range: 10 to 64 years). The trials tested vigabatrin doses between 1 g/day and 6 g/day. All 11 trials displayed a risk of bias across at least three risk of bias domains. Predominantly, the risk of bias was associated with: allocation concealment (selection bias), blinding of outcome assessment (detection bias) and incomplete outcome data (attrition bias). Participants treated with vigabatrin may be two to three times more likely to obtain a 50% or greater reduction in seizure frequency compared with those treated with placebo (RR 2.60, 95% CI 1.87 to 3.63; 4 studies; low‐certainty evidence). Those treated with vigabatrin may also be three times more likely to have treatment withdrawn although we are uncertain (RR 2.86, 95% CI 1.25 to 6.55; 4 studies; very low‐certainty evidence). Compared to placebo, participants given vigabatrin were more likely to experience adverse effects: dizziness/light‐headedness (RR 1.74, 95% CI 1.05 to 2.87; 9 studies; low‐certainty evidence), fatigue (RR 1.65, 95% CI 1.08 to 2.51; 9 studies; low‐certainty evidence), drowsiness (RR 1.70, 95% CI 1.18 to 2.44; 8 studies) and depression (RR 3.28, 95% CI 1.30 to 8.27; 6 studies). Although the incidence rates were higher among participants receiving vigabatrin compared to those receiving placebo, the effect was not significant for the following adverse effects: ataxia (RR 2.76, 95% CI 0.96 to 7.94; 7 studies; very low‐certainty evidence), nausea (RR 3.57, 95% CI 0.63 to 20.30; 4 studies), abnormal vision (RR 1.64, 95% CI 0.67 to 4.02; 5 studies; very low‐certainty evidence), headache (RR 1.23, 95% CI 0.79 to 1.92; 9 studies), diplopia (RR 1.76, 99% CI 0.94 to 3.30) and nystagmus (RR 1.53, 99% CI 0.62 to 3.76; 2 studies; low‐certainty evidence). Vigabatrin had little to no effect on cognitive outcomes or quality of life. Vigabatrin may significantly reduce seizure frequency in people with drug‐resistant focal epilepsy. The results largely apply to adults and should not be extrapolated to children under 10 years old. Short‐term follow‐up of participants showed that some adverse effects were associated with its use. Analysis of longer‐term observational studies elsewhere, however, has demonstrated that vigabatrin use can lead to the development of visual field defects. Background Epilepsy is a common neurological disorder affecting approximately 1 in 100 people. Around 30% of these people cannot control their epilepsy with currently available antiepileptic medication and are said to have drug‐resistant epilepsy. Most often, drug‐resistant epilepsy is focal in nature, meaning that the seizures start in one specific area of the brain. Vigabatrin is an antiepileptic medication that can be used as an add‐on treatment for drug‐resistant focal epilepsy, meaning that it is taken in addition to other antiepileptic medications. Main results We found 11 clinical trials, involving 756 people, which investigated vigabatrin as an add‐on for people with drug‐resistant focal epilepsy. The people in the trials were aged between 10 to 64 years and were given doses of 1 g/day to 6 g/day vigabatrin. We found -Abstract Truncated-

Cerebral MRI abnormalities associated with vigabatrin therapy

Reversible abnormalities in brain magnetic resonance imaging of children with infantile spasms during treatments with Vigabatrin

Risk of vigabatrin‐associated brain abnormalities on MRI: A retrospective and controlled study

Vigabatrin‐associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

Vigabatrin-associated brain abnormalities on MRI in tuberous sclerosis complex patients with infantile spasms: are they preventable?

Therapeutic trial of vigabatrin in refractory infantile spasms

Treatment of Epilepsy: the Gaba-Transaminase Inhibitor, Vigabatrin, Induces Neuronal Plasticity in the Mouse Retina

White Matter Alterations in Familial Cortical Myoclonic Tremor with Epilepsy Type 1

Analysis of Safety and Efficacy of Treatment of Vigabatrin in Infantile Spasms in Tuberous Sclerosis Complex Patients

Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms

Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial

Infantile Spasms and Vigabatrin

Vigabatrin in Epilepsy Related to TSC: Does it PREVeNT AND OR (EPI) STOP Seizures OR... Do We Need Some More STEPS as VI RAP?

Low-Dose Vigabatrin (γ-Vinyl GABA)-Induced Damage in the Immature Rat Brain

Vigabatrin add-on therapy for drug-resistant focal epilepsy.

Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity.

A sensitive period of mice inhibitory system to neonatal GABA enhancement by vigabatrin is brain region dependent

Altered Cerebello‐Motor Network in Familial Cortical Myoclonic Tremor with Epilepsy Type 1

Focal Epilepsy in Children with Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures?

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval